// App-Quantinova.ai

1295 : Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Koji Sasaki

Principal Investigators

  • Paul B. Koller

  • Hagop M. Kantarjian

  • Farhad Ravandi

  • Srdan Verstovsek

  • Naval Daver

  • Deborah A Thomas

  • Maria R. Khouri

  • Guillermo Garcia-Manero

  • Rebecca Garris

  • Jorge E. Cortes

  • Heather Schroeder

  • Jad Chahoud

  • Tapan Kadia

Medical Centers

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, HOUSTON, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of Texas at Houston Health Science Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • 6-mercaptopurine

  • Allmercap

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Asparaginase

  • Vincristine

  • Doxorubicin

  • Cytarabine liposomal

  • ofatumumab Intravenous

  • Prednisone

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved